Results for

Prescription Drug Price Reporting Act This bill requires that all prescription drug manufacturers submit certain information for every drug marketed in the United States to the Department of Health and Human Services (HHS). Specifically, manufacturers must provide information about cost, pricing, and rebates. Manufacturers are also required to submit any price changes to a prescription drug at least 30 days in advance. HHS must make this information available through a public database that enables consumers to subscribe to price change notifications for different types of prescriptions drugs.

Prescription Drug Price Reporting Act This bill requires that all prescription drug manufacturers submit certain information for every drug marketed in the United States to the Department of Health and Human Services (HHS). Specifically, manufacturers must provide information about cost, pricing, and rebates. Manufacturers are also required to submit any price changes to a prescription drug at least 30 days in advance. HHS must make this information available through a public database that enables consumers to subscribe to price change notifications for different types of prescriptions drugs.

Prescription Drug Monitoring Act of 2019 This bill expands the notification and reporting requirements with respect to potentially addictive prescription drugs for states receiving funds for a Prescription Drug Monitoring Program (PDMP). Dispensers of these drugs, which includes substances listed in schedule II, III, or IV of the Controlled Substances Act, must consult with the PDMP before starting treatment involving such drugs and report each prescription of such drugs to the PDMP within 24 hours. The state agency administering a PDMP must analyze reported data for patterns of controlled substance misuse or abuse and provide certain information to law enforcement, the public, and other states.

Prescription Drug Monitoring Act of 2019 This bill expands the notification and reporting requirements with respect to potentially addictive prescription drugs for states receiving funds for a Prescription Drug Monitoring Program (PDMP). Dispensers of these drugs, which includes substances listed in schedule II, III, or IV of the Controlled Substances Act, must consult with the PDMP before starting treatment involving such drugs and report each prescription of such drugs to the PDMP within 24 hours. The state agency administering a PDMP must analyze reported data for patterns of controlled substance misuse or abuse and provide certain information to law enforcement, the public, and other states.

Prescription Drug Rebate Reform Act of 2019 This bill requires private health insurance plans to set any coinsurance rate for a covered prescription drug based on the net price of the drug (the price after accounting for rebates and discounts provided by the drug manufacturer) and not the list price (the initial wholesale price set by the drug manufacturer). This requirement applies when a plan holder has an unmet deductible or other coinsurance obligation for prescription drug benefits under the plan. The bill does not prohibit a plan from requiring a copayment provided that such copayment is not based on the cost of the drug.

Prescription Drug Rebate Reform Act of 2019 This bill requires private health insurance plans to set any coinsurance rate for a covered prescription drug based on the net price of the drug (the price after accounting for rebates and discounts provided by the drug manufacturer) and not the list price (the initial wholesale price set by the drug manufacturer). This requirement applies when a plan holder has an unmet deductible or other coinsurance obligation for prescription drug benefits under the plan. The bill does not prohibit a plan from requiring a copayment provided that such copayment is not based on the cost of the drug.

Affordable and Safe Prescription Drug Importation Act This bill addresses the importation of drugs from Canada and other foreign countries. The bill requires the Food and Drug Administration (FDA) to promulgate regulations within 180 days permitting wholesalers, pharmacies, and individuals to import certain prescription drugs from Canada. After two years, The FDA, may permit the importation of prescription drugs from other countries. The bill establishes a process for certifying foreign sellers—a licensed foreign pharmacy or foreign wholesale distributor.

Affordable and Safe Prescription Drug Importation Act This bill addresses the importation of drugs from Canada and other foreign countries. The bill requires the Food and Drug Administration (FDA) to promulgate regulations within 180 days permitting wholesalers, pharmacies, and individuals to import certain prescription drugs from Canada. After two years, The FDA, may permit the importation of prescription drugs from other countries. The bill establishes a process for certifying foreign sellers—a licensed foreign pharmacy or foreign wholesale distributor.

Medicare Prescription Drug Savings and Choice Act of 2019 This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish at least one prescription drug plan that is operated by Medicare. Among other things, the plan must (1) serve the entire United States; and (2) be the default plan for enrollees under the Medicare prescription drug benefit, unless the enrollee chooses another plan. Additionally, the CMS must negotiate prices for prescription drugs that are covered under the plan and, if appropriate, encourage the use of more affordable therapeutic equivalents. (Currently, the CMS is prohibited from negotiating the prices of covered drugs under the Medicare prescription drug benefit.) The Agency for Healthcare Research and Quality must assess the clinical benefits of drugs and make recommendations to the CMS regarding price negotiations, based on specified information (e.g., comparable international prices).

Medicare Prescription Drug Savings and Choice Act of 2019 This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish at least one prescription drug plan that is operated by Medicare. Among other things, the plan must (1) serve the entire United States; and (2) be the default plan for enrollees under the Medicare prescription drug benefit, unless the enrollee chooses another plan. Additionally, the CMS must negotiate prices for prescription drugs that are covered under the plan and, if appropriate, encourage the use of more affordable therapeutic equivalents. (Currently, the CMS is prohibited from negotiating the prices of covered drugs under the Medicare prescription drug benefit.) The Agency for Healthcare Research and Quality must assess the clinical benefits of drugs and make recommendations to the CMS regarding price negotiations, based on specified information (e.g., comparable international prices).

Medicare Prescription Drug Fraud Prevention Act of 2019 This bill requires prescription drug plan sponsors to report any suspicious activities relating to fraud, waste, or abuse under the Medicare prescription drug benefit and any corrective actions taken.

Prescription Drug Pricing Dashboard Act This bill requires the Department of Health and Human Services to establish an online dashboard containing information about the prices and utilization of prescription drugs that are purchased by federal programs. The dashboard must include specified information, including spending per dosage, the number of drug recipients, and out-of-pocket costs. The dashboard must also highlight those drugs that have the highest spending and costs.

State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019 This bill authorizes health insurance issuers to jointly negotiate the prices for prescription drugs with the manufacturers of such drugs.

Medicare Prescription Drug Price Negotiation Act of2019 This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. Current law prohibits the CMS from doing so.

Lowering Prescription Drug Prices for America's Seniors and Families Act of 2020 This bill makes a series of changes to requirements relating to prescription drug prices. Among other changes, the bill requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain covered drugs under the Medicare prescription drug benefit, allows individuals to import certain drugs from Canada to fill personal prescriptions, and establishes specific enforcement actions against patent infringement agreements that involve generic drug manufacturers and have anticompetitive effects.

Prescription Drug Price Transparency Act This bill establishes additional requirements for prescription drug plan sponsors (PDPs) under Medicare and Medicare Advantage, as well as health insurance carriers under the Federal Employees Health Benefits Program, relating to the methodology of payments to pharmacies and the use of pharmacy benefits managers (PBMs). Specifically, such PDPs and carriers must disclose specified information to pharmacies regarding applicable standards for reimbursement that are based on drug costs, including the sources used to update such standards. Additionally, such PDPs and carriers may not contract with PBMs that require, or that provide an incentive for, plan enrollees to use pharmacies that have a shared ownership interest with the PBM.

Prescription Drug Pricing Reduction Act of2020 This bill alters several programs and requirements relating to the prices of prescription drugs under Medicare and Medicaid. Among other things, the bill * requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services (CMS) for certain drugs covered under Medicare for which the average manufacturer price increases faster than inflation; * requires drug manufacturers to issue rebates to the CMS for discarded amounts of certain single-dose drugs covered under Medicare, based on information reported by providers; * reduces the annual out-of-pocket spending threshold, and eliminates beneficiary cost-sharing above this threshold, under the Medicare prescription drug benefit; * requires the CMS to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to drug discounts and rebates, and payments between PBMs, health plans, and pharmacies; * requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with PBMs under Medicaid; and * increases the maximum rebate payable by drug manufacturers under the Medicaid Drug Rebate Program.

Prescription Drug Pricing Reduction Act of 2019 This bill alters several programs and requirements relating to the prices of prescription drugs under Medicare and Medicaid. Among other things, the bill * requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services (CMS) for certain drugs covered under Medicare for which the average manufacturer price increases faster than inflation; * requires drug manufacturers to issue rebates to the CMS for discarded amounts of certain single-dose drugs covered under Medicare, based on information reported by providers; * reduces the annual out-of-pocket spending threshold, and eliminates beneficiary cost-sharing above this threshold, under the Medicare prescription drug benefit; * requires the CMS to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to drug discounts and rebates, and payments between PBMs, health plans, and pharmacies; * requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with PBMs under Medicaid; and * increases the maximum rebate payable by drug manufacturers under the Medicaid Drug Rebate Program.

Improving Low-Income Access to Prescription Drugs Act of 2019 This bill requires the Centers for Medicare & Medicaid Services to establish a transition program under the Medicare prescription drug benefit for limited-income, newly eligible individuals (i.e., individuals who are eligible for subsidies and have not yet enrolled in, or whose coverage has not yet taken effect under, a Medicare or Medicare Advantage prescription drug plan). Such coverage must provide immediate access to covered drugs at the point of sale as soon as the individual becomes eligible for subsidies; coverage also applies retroactively for dual eligible individuals and for individuals who receive benefits under the Supplemental Security Income program.

Life-Sustaining Prescription Drug Price Relief Act of 2019 This bill establishes a series of oversight and disclosure requirements relating to the prices of life-sustaining prescription drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all life-sustaining drugs for excessive pricing; HHS must also review prices upon petition. HHS must create a public database with its determinations for each drug and report its overall findings and related activities. Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds 110% of the average price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including cost, revenue, and the size of the affected patient population. The bill also requires drug manufacturers, subject to civil penalties, to (1) report specified financial information for life-sustaining drugs, including research and advertising expenditures; and (2) negotiate the prices of excessively priced life-sustaining drugs under the Medicare prescription drug benefit with HHS.

Improving Low-Income Access to Prescription Drugs Act of 2019 This bill requires the Centers for Medicare & Medicaid Services to establish a transition program under the Medicare prescription drug benefit for limited-income, newly eligible individuals (i.e., individuals who are eligible for subsidies and have not yet enrolled in, or whose coverage has not yet taken effect under, a Medicare or Medicare Advantage prescription drug plan). Such coverage must provide immediate access to covered drugs at the point of sale as soon as the individual becomes eligible for subsidies; coverage also applies retroactively for dual eligible individuals and for individuals who receive benefits under the Supplemental Security Income program.

Seniors Prescription Drug Relief Act of 2019 This bill allows beneficiaries whose monthly costs under the Medicare prescription drug benefit equal or exceed a significant percentage of the annual out-of-pocket spending threshold to pay down such costs in installments over the course of the remaining plan year. The Centers for Medicare & Medicaid Services must determine what constitutes a significant percentage; however, such percentage must be between 50% and 100%.

Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or the Prescription Drug STAR Act This bill establishes requirements for prescription drug manufacturers to provide certain information about pricing, discounts, and product samples of applicable drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to annually determine whether there are price increases of a certain threshold for outpatient prescription drugs covered under Medicare, excluding low-cost drugs. Manufacturers must provide HHS with an explanation for drug prices that (1) cumulatively increase by at least 10% or $10,000 over one year; (2) cumulatively increase by at least 25% or $25,000 over three years; or (3) are at least $26,000 annually, per individual, if first covered by Medicare during the applicable year. The manufacturer must explain the role of the factors contributing to such prices and other relevant information, including manufacturing costs, marketing costs, and revenue. Additionally, drug manufacturers must provide HHS with aggregate data related to product samples of drugs, devices, biologic products, and medical supplies given to hospitals, physicians, or other medical professionals during the previous calendar year, beginning in 2023. The bill further requires HHS to make publicly available the information related to drug discounts, rebates, and price concessions that is provided annually to HHS by group health plans. Drug manufacturers also must report to HHS certain sales information for drugs available under Medicare for which the manufacturer does not have a rebate agreement in place. The bill requires HHS to study and report on trends concerning inpatient hospital drug costs.

Strengthening Health Care and Lowering Prescription Drug Costs Act This bill addresses prescription drugs and the health insurance market, including (1) revising processes related to federal approval of generic drugs; (2) providing funding for states to establish health insurances exchanges; (3) nullifying an agency rule related to short-term, limited duration coverage; and (4) expanding outreach activities.

Prescription for American Drug Independence Act of 2020 This bill requires the Department of Health and Human Services to enter into an agreement with the National Academies of Sciences, Engineering, and Medicine to (1) establish a committee of experts on drug-supply issues, (2) convene a symposium to recommend strategies for ending U.S. dependence on foreign manufacturing of critical drugs, and (3) report on the symposium's proceedings.